HALIFAX,
March 3, 2014 /CNW/ - MedMira
Inc., (MedMira) (TSXV: MIR), a developer of rapid testing
technologies and solutions, reported today that the Company's Board
of Directors, Corporate Secretary, and Chief Financial Officer have
been granted options to purchase common shares under its Stock
Option Plan approved at the Company's Annual General Meeting held
on January 25, 2013. Mr.
Hermes Chan, Dr. Shou-Ching Tang, Mr. Romano Robusto, Mr. Markus Meile and Ms. Robyn Cook were granted a total of 1,350,000
options at an exercise price of $0.10
per share and exercisable for a period of two years ending
March 2, 2016. These
individuals, as well as Dr. Michael
Sidler and Mr. Jelle Kuypers,
were granted a total of 1,500,000 options at an exercise price of
$0.10 per share and exercisable for a
period of three years, ending March 2,
2017.
About MedMira
MedMira is a leading developer and manufacturer
of rapid testing technology and solutions. The Company's tests
provide hospitals, labs, clinics and individuals with reliable,
rapid diagnosis for diseases such as HIV and hepatitis C in just
three minutes. The Company's tests are sold under the Reveal®,
Multiplo™ and Miriad™ brands in global markets. MedMira's patented
Rapid Vertical Flow Technology™ is the platform the Company's rapid
testing solutions are built on including its rapid HIV test which
is the only one in the world to achieve regulatory approvals in
Canada, the United States, China and the European Union. MedMira's
corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For
more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking
statements, which involve risk and uncertainties and reflect the
Company's current expectation regarding future events including
statements regarding possible approval and launch of new products,
future growth, and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from
time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE MedMira Inc.
